Longhorn Vaccines

Executive Summary

Longhorn Vaccines is a private biopharmaceutical company based in Bethesda, Maryland, focused on developing prophylactic and therapeutic antibodies to prevent bacterial infections and sepsis. Its lead candidate, LHNVD-501, targets a key cell wall component of pathogenic bacteria that also functions as a toxin, driving inflammation and chronic disease. The dual-action antibody aims to neutralize both the bacterial infection and the toxin-mediated pathology, potentially offering a novel approach to sepsis prevention in high-risk populations. Despite being founded in 2006, the company remains in early development, with no disclosed funding or clinical-stage assets in public databases. While the scientific rationale is compelling, the lack of recent milestones or transparency limits visibility into its progress.

Upcoming Catalysts (preview)

• TBDIND Filing for LHNVD-50120% success
• TBDFirst Clinical Trial Initiation15% success
• TBDStrategic Partnership or Licensing Deal25% success